NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above

MT Newswires Live

07/02

National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.

In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.

The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.

Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.

NICE is a UK-based non-departmental public body of the Department of Health and Social Care.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548600898"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548600898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548600898?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548600898","market":"us","top_or_hot":-1,"title":"NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above","media":"MT Newswires Live","content":"<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNICE Recommends Chugai Pharmaceutical's Nemluvio for Moderate-to-Severe Atopic Dermatitis in Ages 12 and Above\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-02 17:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.</p><p>In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.</p><p>The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.</p><p>Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.</p><p>NICE is a UK-based non-departmental public body of the Department of Health and Social Care.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFMHRM44.USD","symbol_name":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2548600898","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548600898","pubTimestamp":1751449713,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"National Institute for Health and Care Excellence  has recommended Chugai Pharmaceutical's  Nemluvio  for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4023":"应用软件","NICE":"NICE系统","BK4543":"AI","BK4566":"资本集团"},"translate_title":"NICE推荐中外制药的Nemluvio治疗12岁及以上中重度特应性皮炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NICE":1},"content_text":"National Institute for Health and Care Excellence (NICE) has recommended Chugai Pharmaceutical's (TOKYO: 4519) Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and over.In NICE guidance published on July 2, the regulator cited the treatment's potential to address clinical needs and optimize NHS resources.The decision follows two-year interim data from Galderma's ARCADIA extension study, presented at the Revolutionizing Atopic Dermatitis Conference, demonstrating the drug's long-term efficacy as an anti-IL-31 receptor A monoclonal antibody.Chugai developed Nemluvio, while Galderma handles global clinical development and commercialization outside Japan, according to a statement on Chugai's website.NICE is a UK-based non-departmental public body of the Department of Health and Social Care.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}